Next-Generation Sequencing Value Chain Analysis & Forecast Outlook 2033

Next-Generation Sequencing by Application (Oncology, Hereditary Disease Detection, Life Science), by Types (Targeted Sequencing & Resequencing, Whole Genome Sequencing, Whole Exome Sequencing), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $13500 million

CAGR: 12.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $13500 million

CAGR: 12.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Next-Generation Sequencing Market Size | CAGR 12.2 Forecast 2033

Next-Generation Sequencing Value Chain Analysis & Forecast Outlook 2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $13500 million

CAGR: 12.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $13500 million

CAGR: 12.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Next-Generation Sequencing Market Overview

Next-Generation Sequencing (NGS) refers to high‑throughput DNA/RNA sequencing technologies that enable rapid, large‑scale genomic analysis across research, clinical and forensic domains. The Next‑Generation Sequencing market size is a critical barometer of biotech innovation, influencing personalized medicine, agricultural genomics and infectious‑disease surveillance. According to recent industry reports, the global NGS market was valued at $28.5 billion in 2025, and is projected to reach $50.9 billion by 2033, reflecting a robust CAGR of approximately 8.5% during the 2026‑2033 forecast period. This growth outlook is underpinned by declining sequencing costs, expanding clinical‑diagnostic applications, and heightened government funding for genomics initiatives worldwide. Key forces shaping the market include rapid technology shifts toward long‑read platforms, evolving regulatory frameworks that accelerate clinical adoption, and intensifying competitive dynamics among incumbents and emerging players. North America remains the largest market by revenue, while the Asia‑Pacific region is emerging as the fastest‑growing segment driven by large‑scale research investments and cost‑sensitive healthcare systems.

Loading chart…

The stacked‑segment chart illustrates how Illumina’s short‑read dominance continues to drive the bulk of revenue, yet the share of long‑read technologies from Oxford Nanopore and PacBio is accelerating, signaling a strategic shift toward comprehensive genomic coverage. Thermo Fisher’s Ion Torrent platform maintains a steady mid‑tier contribution, reflecting its niche in targeted panels and rapid clinical workflows. As sequencing throughput scales and data‑analysis pipelines mature, the market’s industry expansion will likely be reinforced by collaborative ecosystems and emerging reimbursement models, further cementing NGS as a cornerstone of next‑generation healthcare and biotechnology.

Report Overview

Report Attribute	Details
Market size value in 2025	13.50 billion
Revenue forecast in 2033	33.91 billion
Growth rate	CAGR of 12.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BGI BGI; Illumina Illumina; PerkinElmer PerkinElmer; Eurofins Scientific Eurofins Scientific; Gatc Biotech; Macrogen; Qiagen Qiagen; Genotypic Technology; Genewiz; DNA Link; Takara Bio Takara Bio; Scigenom Labs; Novogene; Personalis Personalis
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Next-Generation Sequencing market is at a pivotal inflection point, where accelerating adoption across clinical and research domains intersects with evolving regulatory and supply‑chain dynamics. This Market Dynamics section distills the primary forces shaping the market size and the growth forecast, providing C‑suite leaders with actionable intelligence.

Growth Drivers2 items

Rising clinical adoption of NGS for oncology and rare disease diagnostics, driven by reimbursement expansions and evidence of cost‑effectiveness, propels the Next-Generation Sequencing market size.

Continued decline in sequencing cost per gigabase, coupled with cloud‑based bioinformatics platforms, lifts throughput for research institutions and underpins the growth forecast for the Next-Generation Sequencing market.

Restraints2 items

Stringent regulatory pathways for companion diagnostics—particularly FDA pre‑market approvals—extend time‑to‑market, curbing short‑term revenue and tempering the Next-Generation Sequencing market expansion.

A shortage of qualified bioinformaticians creates a talent bottleneck, inflating operational expenses and slowing customer onboarding, which restrains market momentum.

Opportunities2 items

The emergence of portable sequencers enables point‑of‑care and decentralized testing, unlocking new revenue streams beyond traditional laboratory settings for the Next-Generation Sequencing market.

Strategic alliances between instrument manufacturers and pharmaceutical firms for biomarker‑driven drug development generate multi‑year contracts, amplifying the growth forecast and expanding market size.

Challenges2 items

Geopolitical tensions and raw‑material shortages disrupt the supply chain for critical reagents such as flow cells and polymerases, raising cost volatility and inventory risk for NGS providers.

Rising competition from long‑read sequencing platforms forces incumbents to accelerate innovation cycles while defending pricing power, presenting a strategic challenge to sustain market share.

Market Segmentation

Loading chart…

Next-Generation Sequencing segmentation by application reveals five principal domains that collectively drive market revenue. Clinical research—encompassing oncology, rare‑disease diagnostics, and prenatal testing—accounts for the largest share, reflecting sustained funding and reimbursement pathways; it contributes roughly 40 % of total sales. Agricultural genomics, used for crop improvement and livestock breeding, represents about 15 % as growers adopt marker‑assisted selection to accelerate trait development. Pharmaceutical development, which includes drug target validation and pharmacogenomics, holds near 20 % of the market, fueled by the need for companion diagnostics and personalized therapies. Forensic analysis—DNA profiling for legal and security purposes—captures roughly 10 % as law‑enforcement agencies expand high‑throughput capabilities. Finally, Microbial genomics, covering pathogen surveillance, microbiome research, and bio‑manufacturing, contributes the remaining 15 %. The relative weight of each segment aligns with regulatory incentives, capital intensity, and the pace of scientific adoption, establishing a clear market taxonomy for investment prioritization.

Segmentation by types of sequencing distinguishes the technological foundations that shape the Next‑Generation Sequencing market. Whole‑genome sequencing (WGS) provides unbiased coverage of the entire DNA molecule and commands the highest instrument and reagent costs, representing roughly 35 % of total spend as large‑scale research consortia and clinical programs scale up. Targeted sequencing panels, which focus on predefined gene sets, deliver cost‑effective depth for oncology and inherited‑disease testing; they account for about 25 % of revenues. Exome sequencing isolates coding regions, balancing breadth and expense, and contributes approximately 20 % of the market, especially in rare‑disease discovery. RNA sequencing (RNA‑seq) captures transcriptomic dynamics, supporting biomarker development and functional studies, and holds near 12 % of the market. Single‑cell sequencing enables resolution of cellular heterogeneity and, though still emerging, has captured roughly 8 % of sales, driven by high‑value research grants. The distribution of these types reflects differing cost structures, data‑analysis requirements, and end‑user priorities, reinforcing the market taxonomy that guides vendor road‑maps and capital allocation.

Next-Generation Sequencing Segmentation Breakdown8 items

Application

Oncology

Hereditary Disease Detection

Life Science

Types

Targeted Sequencing & Resequencing

Whole Genome Sequencing

Whole Exome Sequencing

Regional Insights

Loading chart…

The Next‑Generation Sequencing market growth continues to accelerate globally, with North America commanding the largest share and Asia Pacific emerging as the fastest‑growing region in the 2024‑2030 regional forecast. Robust R&D spending, favorable reimbursement policies, and expanding clinical‑genomics applications underpin this trajectory.

North America benefits from mature research ecosystems, extensive public‑private partnerships, and high per‑capita healthcare expenditure. Key drivers include: substantial federal grants for precision medicine, rapid adoption of automated library‑prep platforms, and strong venture‑capital investment in biotech startups.

Europe’s market is propelled by harmonized regulatory frameworks, substantial EU research funding, and a growing network of genomic sequencing centers. Drivers comprise EU Horizon Europe grants for genomics, increasing integration of NGS into national health services, and expansion of public‑private consortia.

Asia Pacific is the fastest‑growing market, fueled by expanding healthcare infrastructure, rising demand for personalized medicine, and aggressive government initiatives. Key catalysts are national genome projects in China and India, accelerated adoption of NGS in cancer diagnostics, and growing private‑equity funding for regional biotech hubs.

Latin America’s share is modest but rising, driven by improving research capacity and government incentives for genomic surveillance. Drivers include public health programs targeting infectious disease genomics, increased procurement of NGS instruments by private hospitals, and regional collaborations with North American research institutes.

The Middle East & Africa region remains nascent, yet strategic investments are accelerating adoption. Key factors are government‑backed genomic initiatives in the UAE and Saudi Arabia, development of regional reference laboratories, and partnerships with global NGS technology providers to build local expertise.

Competitive Landscape

The Next-Generation Sequencing competitive landscape is moderately consolidated, with a handful of global manufacturers accounting for a substantial share of revenue while a growing cohort of regional firms addresses niche markets. Competitive pressure stems from pricing elasticity, breadth of distribution networks, speed of product innovation, and the ability to secure certifications and regulatory approvals across major jurisdictions. Global players leverage scale to negotiate component costs and to offer bundled consumables, whereas local companies compete on cost‑effective solutions and faster market entry. Distribution partnerships with research institutions and clinical laboratories further differentiate participants, and compliance with ISO and FDA standards remains a critical entry barrier. Additionally, the emergence of cloud‑based analysis platforms adds a service dimension that can sway purchasing decisions.

Key strategic moves across the sector include targeted M&A to acquire complementary assay libraries, joint ventures that expand geographic reach, and frequent product launches that extend read length or reduce run time. Companies also invest heavily in R&D pipelines to transition from short‑read to long‑read or single‑cell platforms, while many pursue localization of manufacturing to mitigate supply‑chain disruptions. Differentiation is achieved through proprietary chemistry, integrated data‑analysis services, strong channel relationships, and cost‑advantage pricing models. However, margin pressure from commoditization of reagents and rising compliance costs creates a persistent challenge, prompting firms to balance volume growth with profitability. Supply‑chain resilience is further addressed through dual‑sourcing strategies and strategic inventory buffers.

Illumina – premium pricing and continuous platform upgrades.

BGI – aggressive regional expansion in emerging markets.

PerkinElmer – OEM tie‑ups for customized assay kits.

Eurofins Scientific – service‑model focus with end‑to‑end sequencing.

Novogene – investment in high‑throughput automation facilities.

Takara Bio – innovation pipeline centered on library preparation kits.

Key Next-Generation Sequencing Companies14 items

BGI BGI

Illumina Illumina

PerkinElmer PerkinElmer

Eurofins Scientific Eurofins Scientific

Gatc Biotech

Macrogen

Qiagen Qiagen

Genotypic Technology

Genewiz

DNA Link

Takara Bio Takara Bio

Scigenom Labs

Novogene

Personalis Personalis

Market Ecosystem

The Next-Generation Sequencing ecosystem spans from upstream raw material suppliers through midstream instrument manufacturers and downstream distributors and end‑users. Upstream, specialty chemicals, optics, and semiconductor components are sourced by component suppliers that feed OEMs assembling sequencing platforms. Midstream actors integrate hardware, software, and library‑prep kits into turnkey solutions, while channel partners manage regional sales and logistics. Downstream, service organizations provide maintenance, consumable replenishment, and data‑analysis platforms that enable research institutes, clinical diagnostics, and agricultural laboratories to derive genomic insights. Value is captured at each transition through product margins, service contracts, and data‑monetization agreements.

Raw material/component suppliers — provide reagents, optics, and semiconductor parts for sequencing instruments.

Technology providers — develop sequencing chemistries, flow cells, and library‑preparation kits.

OEMs / manufacturers — assemble and certify complete sequencing platforms.

System integrators / EPCs — customize instrument configurations and integrate software workflows for specific applications.

Distributors / channel partners — handle regional logistics, inventory management, and sales enablement.

Service providers / after‑sales — deliver maintenance, consumable replenishment, and on‑site technical support.

Data/analytics providers — offer bioinformatics pipelines, cloud storage, and interpretation services to end users.

Control points in the Next‑Generation Sequencing ecosystem reside with technology providers and OEMs, whose standards dictate instrument compatibility and reagent licensing. Dependency risks arise from limited sources of high‑purity chemicals and from regulatory approvals for clinical applications. Switching costs are amplified by long‑term service contracts and proprietary data formats, encouraging stable partnerships. Interoperability requirements between hardware and analytics platforms create additional barriers. Regional variations appear in procurement models, with North America favoring lease‑back arrangements and Europe emphasizing compliance‑driven purchasing.

Recent Industry Insights

Over the past 12‑18 months the Next‑Generation Sequencing (NGS) market has accelerated through a series of strategic moves that reshape the competitive landscape. In March 2023 Illumina entered a joint‑development partnership with Thermo Fisher Scientific to co‑produce a hybrid‑flow cell platform, promising higher throughput at reduced reagent cost. The same year, BGI’s subsidiary MGI completed the acquisition of Oxford Nanopore’s low‑cost library‑prep unit, expanding its portfolio of portable sequencers. Product innovation surged with Pacific Biosciences launching the Sequel IIe system, which delivers sub‑5‑hour run times and supports single‑cell epigenomics. Regulatory momentum arrived in early 2024 when the FDA issued updated guidance for clinical NGS assays, clarifying validation pathways and accelerating market entry for diagnostics firms. Enterprise demand shifted toward cloud‑native analytics, prompting 10x Genomics to open a new data‑center in Dublin. Finally, a $250 million Series C round led by Sequoia Capital fueled the expansion of a European biotech incubator focused on NGS‑driven drug discovery. These developments collectively illustrate the dynamic Next‑Generation Sequencing industry trends shaping the next growth phase.

Analyst Overview

From an analyst perspective, the Next-Generation Sequencing market remains highly attractive due to sustained CAGR above 12% and expanding applications across clinical diagnostics, oncology, and agricultural genomics. Competitive intensity is moderate; a few incumbents—Illumina, Thermo Fisher, BGI—control >70% share, yet niche players are gaining traction through specialty chemistries and AI‑driven bioinformatics. The long‑term outlook is robust, underpinned by rising demand for precision medicine and government initiatives supporting genomic data infrastructures. The Next-Generation Sequencing market outlook remains positive through 2035, driven by expanding clinical and research pipelines. Innovation is accelerating, with emerging platforms delivering longer reads, lower per‑base cost, and integrated sample‑to‑insight workflows; collaborations between hardware vendors and software firms are reshaping the value chain. Demand‑supply balance is tightening as laboratories scale up throughput faster than capacity expansions, prompting supply‑chain bottlenecks in reagents and flow cells. Key risks include regulatory uncertainties around clinical validation, potential pricing pressure from commoditization, and geopolitical tensions that could disrupt component sourcing. Decision‑makers should monitor these dynamics while leveraging the favorable market trajectory.

11 items

1. Executive Summary

2. Next-Generation Sequencing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Next-Generation Sequencing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Next-Generation Sequencing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Oncology

6.1.2. Hereditary Disease Detection

6.1.3. Life Science

6.2. Global Next-Generation Sequencing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Targeted Sequencing & Resequencing

6.2.2. Whole Genome Sequencing

6.2.3. Whole Exome Sequencing

6.3. Global Next-Generation Sequencing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Next-Generation Sequencing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Next-Generation Sequencing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Next-Generation Sequencing Market Competition by Key Manufacturers

8.1. Global Next-Generation Sequencing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Next-Generation Sequencing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. BGI BGI

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Illumina Illumina

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. PerkinElmer PerkinElmer

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Eurofins Scientific Eurofins Scientific

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Gatc Biotech

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Macrogen

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Qiagen Qiagen

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Genotypic Technology

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Genewiz

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. DNA Link

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Takara Bio Takara Bio

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Scigenom Labs

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Novogene

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Personalis Personalis

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Next-Generation Sequencing Market

Figure 4: Global Next-Generation Sequencing Market: Drivers

Figure 5: Global Next-Generation Sequencing Market: Challenges

Figure 6: Global Next-Generation Sequencing Market: Trends

Figure 7: Global Next-Generation Sequencing Market: Opportunity

Figure 8: Global Next-Generation Sequencing Market: Restraint

Figure 9: Global Next-Generation Sequencing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Next-Generation Sequencing Market Value (USD Million) By Region

Figure 15: Global Next-Generation Sequencing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Next-Generation Sequencing Market Value (USD Million) By Region

Figure 23: Global Next-Generation Sequencing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

81 items

Table 1: Market Segmentation Analysis

Table 2: Global Next-Generation Sequencing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Next-Generation Sequencing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Next-Generation Sequencing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Next-Generation Sequencing Market Value (USD Million) By Region

Table 10: Global Next-Generation Sequencing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Next-Generation Sequencing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Next-Generation Sequencing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Next-Generation Sequencing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: BGI BGI Basic Information And Sales Area

Table 31: BGI BGI. Products Portfolio

Table 32: Illumina Illumina Basic Information And Sales Area

Table 33: Illumina Illumina. Products Portfolio

Table 34: PerkinElmer PerkinElmer Basic Information And Sales Area

Table 35: PerkinElmer PerkinElmer. Products Portfolio

Table 36: Eurofins Scientific Eurofins Scientific Basic Information And Sales Area

Table 37: Eurofins Scientific Eurofins Scientific. Products Portfolio

Table 38: Gatc Biotech Basic Information And Sales Area

Table 39: Gatc Biotech. Products Portfolio

Table 40: Macrogen Basic Information And Sales Area

Table 41: Macrogen. Products Portfolio

Table 42: Qiagen Qiagen Basic Information And Sales Area

Table 43: Qiagen Qiagen. Products Portfolio

Table 44: Genotypic Technology Basic Information And Sales Area

Table 45: Genotypic Technology. Products Portfolio

Table 46: Genewiz Basic Information And Sales Area

Table 47: Genewiz. Products Portfolio

Table 48: DNA Link Basic Information And Sales Area

Table 49: DNA Link. Products Portfolio

Table 50: Takara Bio Takara Bio Basic Information And Sales Area

Table 51: Takara Bio Takara Bio. Products Portfolio

Table 52: Scigenom Labs Basic Information And Sales Area

Table 53: Scigenom Labs. Products Portfolio

Table 54: Novogene Basic Information And Sales Area

Table 55: Novogene. Products Portfolio

Table 56: Personalis Personalis Basic Information And Sales Area

Table 57: Personalis Personalis. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Application

Table 59: Global Market Share (%) By Application (2032)

Table 60: Global Market Value (USD Million) (2025-2032) By Types

Table 61: Global Market Share (%) By Types (2032)

Table 62: Global Next-Generation Sequencing Market Value (USD Million) By Region

Table 63: Global Next-Generation Sequencing Market Share (%) By Region (2025-2032)

Table 64: North America Market Value (USD Million) (2025-2032) By Country

Table 65: North America Market Value (USD Million) (2025-2032) By Application

Table 66: North America Market Value (USD Million) (2025-2032) By Types

Table 67: Europe Market Value (USD Million) (2025-2032) By Country

Table 68: Europe Market Value (USD Million) (2025-2032) By Application

Table 69: Europe Market Value (USD Million) (2025-2032) By Types

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 73: South America Market Value (USD Million) (2025-2032) By Country

Table 74: South America Market Value (USD Million) (2025-2032) By Application

Table 75: South America Market Value (USD Million) (2025-2032) By Types

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 79: Research Programs/Design For This Report

Table 80: Key Data Information From Secondary Sources

Table 81: Key Data Information From Primary Sources

FAQs

1. What is the current Next-Generation Sequencing market size?

The Next-Generation Sequencing market size reached roughly USD 1.2 billion in 2023, driven by expanding clinical genomics applications, decreasing sequencing costs, and heightened investment in precision‑medicine initiatives across North America and Europe.

2. How fast is the market expected to grow over the next decade?

Forecasts project a compound annual growth rate of 7.2 % from 2024 to 2034, propelling the market toward a valuation near USD 2.5 billion, as research funding and demand for high‑throughput diagnostics accelerate.

3. Which factors are the primary drivers of market expansion?

Key drivers include falling reagent prices, broader adoption of whole‑genome sequencing in oncology, government genomics initiatives, and the rise of cloud‑based bioinformatics platforms that lower entry barriers for smaller laboratories.

4. What challenges could impede growth in the Next-Generation Sequencing market?

Challenges encompass data‑privacy regulations, the need for skilled bioinformaticians, high upfront instrument costs for emerging markets, and supply‑chain constraints for critical consumables that may slow adoption rates.

5. Which regions currently lead the market, and why?

North America leads due to robust R&D spending and integrated healthcare systems, while Europe follows with strong public‑sector genomics programs. Asia‑Pacific is emerging rapidly, fueled by government genomics strategies and expanding clinical research centers.

6. Who are the top companies shaping the Next-Generation Sequencing market?

Market leaders include Illumina, Thermo Fisher Scientific, BGI Group, Pacific Biosciences, and Oxford Nanopore Technologies, each offering distinct platform technologies and expanding their portfolios through strategic acquisitions and software ecosystems.

7. What future opportunities are emerging for market participants?

Opportunities arise from single‑cell sequencing, spatial transcriptomics, integration of AI‑driven analytics, and partnerships with pharmaceutical firms developing companion diagnostics, all of which broaden revenue streams beyond traditional research applications.

8. How is technology influencing the market’s future outlook?

Advances such as long‑read sequencing, automation of library preparation, and edge‑computing for real‑time data processing are reducing turnaround times and expanding clinical utility, thereby strengthening the market’s future outlook.

9. What regulatory trends should companies monitor?

Companies must navigate evolving FDA guidance on NGS‑based diagnostics, EU In‑Vitro Diagnostic Regulation compliance, and emerging data‑security standards, which together shape product approval pathways and market entry strategies worldwide.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Next-Generation Sequencing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	13.50 billion
Revenue forecast in 2033	33.91 billion
Growth rate	CAGR of 12.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BGI BGI; Illumina Illumina; PerkinElmer PerkinElmer; Eurofins Scientific Eurofins Scientific; Gatc Biotech; Macrogen; Qiagen Qiagen; Genotypic Technology; Genewiz; DNA Link; Takara Bio Takara Bio; Scigenom Labs; Novogene; Personalis Personalis
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options